Results 61 to 70 of about 18,187,223 (191)
Advancing In Vivo Chimeric Antigen Receptor T‐Cell Engineering to Accelerate Clinical Translation
In vivo CAR‐T cell generation directly engineers endogenous T cells using pre‐manufactured gene delivery vectors that target T cells and deliver CAR‐encoding genetic material. The resulting CAR‐T cells expand in vivo and mediate antigen‐specific cytotoxicity.
Zhenxin Bai +6 more
wiley +1 more source
Summary The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL.
Andrea Gallamini +15 more
wiley +1 more source
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn +17 more
wiley +1 more source
Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance
NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang +3 more
wiley +1 more source
ABSTRACT Background Reports of immune checkpoint inhibitor (ICI) therapy‐associated immune‐related adverse events (irAEs) exhibit considerable heterogeneity, particularly when comparing data from clinical trials and real‐world observational studies. Methods We conducted a systematic review of real‐world observational studies (case reports and series ...
Shea‐Lee Godin +4 more
wiley +1 more source
Peripheral T-cell lymphoma (PTCL) encompasses a heterogeneous group of neoplasms with generally poor clinical outcome. Currently 50% of PTCL cases are not classifiable: PTCL-not otherwise specified (NOS).
Connors, J.M. +111 more
core +2 more sources
The role of the tumor microenvironment in leukemias and lymphomas is well established, yet the intricacies of how the malignant cells regulate and influence their non-malignant counterparts remain elusive.
Christine E. Cutucache, Tyler A. Herek
doaj +1 more source
ABSTRACT Ten‐Eleven Translocation 2 (TET2) is an Fe(II)‐ and α‐ketoglutarate‐dependent dioxygenase that initiates active DNA demethylation by oxidizing 5‐methylcytosine (5mC). Beyond this enzymatic role, TET2 links DNA methylation dynamics with chromatin regulation, cellular metabolism, immune‐cell identity, and treatment response in a context ...
XiaoJie Liu +5 more
wiley +1 more source
Angioimmunoblastic T-cell lymphoma presenting with an acute serologic Epstein-Barr virus profile
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive peripheral T-cell lymphoma typically characterized by prominent lymphadenopathy and B-symptoms at the time of presentation, polyclonal hypergammaglobulinemia, autoimmune hemolysis and frequent ...
Timothy Beer, Patrick Dorion
doaj +1 more source
ABSTRACT Introduction Denileukin diftitox (DD)‐cxdl, a fusion protein comprising diphtheria toxin fragments and human interleukin‐2, is a treatment for peripheral T‐cell lymphoma (PTCL) and cutaneous T‐cell lymphoma (CTCL). Previous trials have enrolled a limited number of patients, and there is a need to evaluate DD‐cxdl in a more diverse population ...
Tatsuro Jo +3 more
wiley +1 more source

